Sign In
26 Oct 2021 13:55
e-therapeutics plc
("e-therapeutics" or the "Company")
Â
Director Dealing
Â
Â
Oxford, UK, 26 October 2021Â - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces the following dealing in the Company's ordinary shares of 0.1 pence each ("Ordinary Shares").
Â
Earlier today, Mr Ali Mortazavi, the Company's Chief Executive Officer, purchased 275,000 Ordinary Shares at a price of 36.5 pence each.
Â
Following the transaction, Mr Mortazavi is benefically interested in 50,941,666 Ordinary Shares, representing 9.9% of the Company's total issued share capital.
Â
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
Â
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Ali Mortazavi |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | e-therapeutics plc |
b) | LEI | 21380049RHSSJXWKYT18 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence  ISIN: GB00B2823H99 |
b) | Nature of the transaction | Purchase of shares |
c) | Price(s) and volume(s) | 275,000 ordinary shares at a price of 36.5 pence per share |
d) | Aggregated information - Aggregated volume - Price  | 275,000 ordinary shares 36.5 pence per share Aggregated value: £100,375 |
e) | Date of the transaction | 26 October 2021 Â |
f) | Place of the transaction | AIM |
Â
Â
Â
Enquiries:
e-therapeutics plc | Tel: +44 (0)1993 883 125 |
Ali Mortazavi, CEO | www.etherapeutics.co.uk |
Karl Keegan, CFO | Â |
 |  |
 SP Angel Corporate Finance LLP |  Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker | Â |
Matthew Johnson/Caroline Rowe (Corporate Finance) | Â |
Vadim Alexandre/Rob Rees (Corporate Broking) | Â |
Â
Â
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
Â
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
Â
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
Â
Â
Follow the stocks
